A JMP Securities analyst maintained CureVac NV (NASDAQ: CVAC) at Market Outperform and a price target of $24.00 from a prior price target of $34.00. Prior to this rating, CureVac NV had 5...
Investing.com - CureVac NV (NASDAQ: CVAC) reported first quarter EPS of €-0.48, €0.17 worse than the analyst estimate of €-0.31. Revenue for the quarter came in at...
By Louis Juricic Shares of CureVac (NASDAQ:CVAC), a biopharmaceutical company developing medicines based on mRNA, climbed 10% early on Thursday after it was upgraded to "Buy" by analysts at...
Investing.com - CureVac NV reported on Wednesday third quarter {{erl-1164707||earnings that beat analysts' forecasts and revenue that fell short of expectations. CureVac NV announced...
CureVac N.V. (CVAC) reported Q3 results. Revenue for the quarter came in at $11.2 million versus the consensus estimate of $20.33 million.
CureVac N.V. (Nasdaq: CVAC) today announced financial results for the first quarter of 2022 and provided a business update."In the past quarter, we have leveraged our core competencies in...
CureVac N.V. (CVAC) today announced financial results for the fourth quarter and full-year 2021 and provided a business update."Going into 2022, we are strengthening our competitive position...
By Dhirendra Tripathi Investing.com – CureVac stock (NASDAQ:CVAC) plunged 15% in Tuesday’s premarket trading to its lowest since the start of the pandemic, as the company dumped...
By Peter Nurse Investing.com - U.S. stocks are seen opening mixed Thursday, consolidating near record levels at the start of the second half of the year and ahead of the release of weekly...
Investing.com – U.S. equities were mixed at the close on Thursday, as gains in the Technology, Healthcare and Consumer Services sectors propelled shares higher while losses in the Oil & Gas,...
By Dhirendra Tripathi Investing.com -- CureVac (NASDAQ:CVAC) shares dropped 38% in Thursday’s premarket trading after its candidate for COVID-19 vaccine failed to meet its main goal in late...
By Christiana Sciaudone Investing.com -- CureVac NV (NASDAQ:CVAC) tumbled almost 13% after Reuters reported the European Medicines Agency is unlikely to make a decision on its vaccine before...
(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window.) * Futures up: Dow 0.3%, S&P 0.4%, Nasdaq 0.6% By Devik Jain Jan 7 (Reuters) -...
By Anthony Esposito and Adriana BarreraMEXICO CITY, Aug 30 (Reuters) - Mexico is pressing ahead with an effort to forge COVID-19 vaccine alliances across a wide ideological spectrum of...
By Christiana Sciaudone Investing.com -- CureVac jumped 14% after the EU concluded a first round of talks for 225 million doses of a potential Covid-19 vaccine. Curevac Bv (NASDAQ:CVAC)...
(For a live blog on the U.S. stock market, click LIVE/ or type LIVE/ in a news window.)* Applied Materials Inc rises on strong Q4 outlook* Retail sales rise 1.2% in July vs 7.5% gain in...
By Christiana Sciaudone Investing.com -- Initial public offerings keep surprising. Curevac Bv (NASDAQ:CVAC), a German biopharmaceutical company working on a coronavirus vaccine, opened...
(For a live blog on the U.S. stock market, click LIVE/ or type LIVE/ in a news window.)* Applied Materials Inc rises on strong Q4 outlook* Retail sales rise 1.2% in July vs 7.5% gain in...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
